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AbStRACt
Objectives: To demonstrate the presence of circulating autoantibodies (Abs) from patients with 
chronic periodontitis (CP) that interacted with human gingival fibroblast membranes activating β1 
adrenoceptors (β1-AR). 
Methods: Sera and purified IgG from 25 patients with CP and 20 age-matched healthy subjects 
were studied by flow cytometry, ELISA and DNA synthesis. Human gingival fibroblast membranes 
and/or synthetic peptides with amino acid sequences identical to human β1-AR were used as antigens.
Results:  By  flow  cytometry  and  ELISA  procedures,  we  proved  that  the  serum-purified  IgG 
fraction from patients with CP reacted with the fibroblast surface and to the β1 synthetic peptide. 
The corresponding affinity-purified anti-β1 peptide Abs displayed agonist-like activity associated with 
specific receptor activation, inhibiting the DNA synthesis of human gingival fibroblasts. 
Conclusions: This study demonstrates that β1-AR autoantibodies are elevated in patients with 
CP. These autoantibodies  were  targeted to the fibroblasts, and specifically to the β1-AR, and has 
receptor-like activity inhibiting DNA synthesis. (Eur J Dent 2009;3:191-199)
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INtRoduCtIoN
Data  from  epidemiologic  studies  have 
suggested  that  periodontal  diseases  are 
multifactorial.1,2  Patient variables, such as age, 
race, smoking, and stress or local hyperactivation 
of  the  autonomic  adrenergic  system  are 
important cofactors which contribute to both the 
prevalence of disease and the incidence of disease European Journal of Dentistry
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progression.3  Moreover,  immunologic  factors 
associated  with    infections  caused  by  selected 
organisms  within  the  sub-gingival  plaque  are 
essential and dominant risk factors for modelling 
periodontal diseases severity.4
The  cellular  and  molecular  events  of 
pathogenesis  consider  that  both  the  effects  of 
serum  on  bacteria  and  neutrophil-bacterial 
interactions  are  associated  with  the  acute 
inflammatory  response5  that  ultimately  results 
in bone resorption and loss of connective tissue 
support.6 The pathogenesis of periodontal disease 
includes  locally  synthesized  biological  products,   
such as enzymes produced by fibroblasts or bone 
cells,  bacterial-specific  immunoglobulin  (Ig) 
secretion,  and  soluble  inflammatory  mediators, 
including  cytokines  and  prostaglandins  and 
cellular  or  tissue  degradation  products.6,7 
Although  many  products  have  been  associated 
with the presence of inflammation,8 few have been 
demonstrated to be associated with a progressive 
autoimmune disorder.
The  autoimmune  concept  established  the 
foundation of a paradigm of disease susceptibility 
and  progression  which  emphasize  not  only 
the  virulence  of  the  microbial  pathogens,  but 
also  considers  the  role  of  the  host  response  in 
regulating  and  limiting  both  the  composition  of 
the  local  flora  and  the  magnitude  of  the  tissue 
destruction. Thus, in periodontal disease during 
the  process  of  combating  pathogenic  invasion, 
the  immune  system  may  cause  localized  tissue 
damage9  and  activate  the  systemic  humoral 
immune response.10
Detection of elevated immunity to type I collagen 
in sera of patients with periodontal disease led to 
the suggestion that autoimmunity may play a role 
in  periodontal  disease.11  This  was  supported  by 
Anusaksathien et al12 who demonstrated that the 
levels of antibodies to collagen type I in periodontal 
tissues were above the levels detectable in serum 
from the same patients, suggesting autoantibody 
production  occurs  predominantly  at  the  sites 
of  disease.  Local  production  of  antibodies  to 
autoantigens in granulomatous tissues contained 
within the periodontal lesion has been reported.13 
Furthermore,  the  autonomic  adrenergic 
system is an important regulator of the immune 
response14 and modified fibroblast DNA synthesis.15 
On  the  basis  of  the  autoimmune  hypothesis  of 
periodontal disease,16-21 we focused our research 
on the possibility of a gingival fibroblast specific 
antigen-antibody  interaction  in  the  disease.  We 
investigated the adrenergic system, by screening 
sera  of  patients  with  periodontal  disease  for 
autoantibodies against β-adrenergic receptors (β1-
AR). Thus, we studied the molecular interactions 
between  circulating  antibodies  from  sera  of 
patients with chronic periodontitis (CP) and human 
β1-AR positive fibroblasts, pointing to the role of 
the  second  extracellular  loop  of  the  receptors 
as the main target of human antibody-mediated 
biological effects.
The  aim  of  this  work  was  to  analyze  the 
presence  of  circulating  autoantibodies  from  CP 
patients  which  interact  with  gingival  fibroblasts 
and  activate  β1-AR.  The  results  demonstrated 
that  these  autoantibodies  were  targeted  to  the 
fibroblasts,  and  specifically  to  the  β1-AR.  The 
autoantibodies  exhibited  adrenergic  agonistic 
activity by inhibiting DNA synthesis measured by 
3H-thymidine incorporation. 
MAtERIALS ANd MEtHodS
Patients
The study group consisted of 25 adult patients 
with CP who were attending the Periodontology 
Clinics  from  the  metropolitan  area  of  Buenos 
Aires. There were 20 males and 5 females, with a 
mean age of 49 years and a range of 42-62 years. 
Healthy subjects were used as controls (20 normal 
subjects  [17  males  and  3  females]),  with  mean 
age of 47 years and a range of 40-60 years. The 
characteristic  clinical  signs  of  CP  included  the 
following: loss of clinical attachment, horizontal 
or/and  angular  alveolar  bone  loss,  periodontal 
pocket formation, and gingival inflammation. To 
be  included  in  the  study,  at  least  six  sites  with 
ongoing  periodontal  disease  were  required. 
Clinical  measurements  on  patients  with  cPD 
included the following:  sites with alveolar bone 
loss  >  2  mm  and  pocket  depth  >  5  mm  with 
bleeding and attachment loss > 3 mm. In healthy 
subjects (control group), the probing depth was < 
3 mm and the attachment loss was < 2 mm.  None 
of the subjects (patients in group 1 and controls in 
group 2) had systemic illnesses and they were not 
smokers. The patients with cPD had not received 
periodontal  treatment  or  antibiotics  within  the 
preceding  5  months  or  any  antiinflammatory 
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drugs  3  weeks  prior  to  the  study.  All  of  the 
patients consented to participate in the study and 
the investigation was conducted according to the 
tenets of the Declaration of Helsinki.
Cell Culture
Human gingival fibroblasts were taken from a 
medically healthy donor, who was clinically free of 
periodontal disease. The healthy tissue appeared 
firm,  non-erythematous,  non-edematous,  and 
was non-bleeding. Samples were obtained from 
donors who gave informed consent for this study. 
The gingival tissue was surgically excised from the 
maxilla and washed six times with normal saline 
to  remove  blood  from  the  surface  and  stored 
in  pre-weighed  containers  in  liquid  nitrogen. 
Gingival tissue was subsequently minced in small 
pieces and seeded in well plates using Dulbecco’s 
modified Eagle’s medium  supplemented with 10% 
fetal bovine serum (FBS), 2 mM L-glutamine, and 
penicillin  (100  U/ml)  and  streptomycin  (100  Ug/
ml) in a 5% CO2 environment at 37ºC, as described 
by  Varani  et  al.22  The  medium  was  replenished 
every 3-4 days. Confluent cells were sub-cultured 
by detaching the monolayer with 0.25% trypsin in 
phosphate  buffered  saline  solution  (PBS).  Cells 
were used between passages 6-8.
Human sera and IgG purification
Sera and the corresponding IgG were obtained 
from groups 1 and 2. Six ml of blood was obtained 
by  venipuncture  and  allowed  to  clot  at  room 
temperature, serum separated by centrifugation 
at  2000  g,  and  stored  at  -20ºC  until  used  in 
assays.  The  IgG  was  obtained  by  precipitation 
with  ammonium  sulphate  at  50%,  followed  by 
three  washes  and  re-precipitation  with  33% 
ammonium  sulphate.  The  resulting  precipitate 
was  submitted  to  chromatography  on  DEAE-
cellulose,  equilibrated  with  10  mM  phosphate 
buffer (pH 8). The eluted peaks were concentrated 
by  ultrafiltration  to  10  mg  protein/ml.  Control 
immune  electrophoresis  with  goat  anti-human 
total serum and goat non-specific anti-human IgG 
showed only one precipitin line.
Purification of antipeptide antibodies by 
affinity chromatography
The  IgG  fraction  of  25  patients  with  CP  was 
independently subjected to affinity chromatography 
on  the  synthesized  peptide  covalently  linked  to 
Affi-Gel 15 gel (Bio-Rat, Richmond, CA, USA). The 
IgG  fraction  was  loaded  on  the  affinity  column 
equilibrated  with  PBS,  and  the  non-peptide 
fraction  was  first  eluted  with  the  same  buffer. 
Specific  anti-peptide  autoantibodies  were  then 
eluted with 3 M KSCN and 1 M NaCl, followed by 
immediate extensive dialysis against PBS. The IgG 
concentration of both non-antipeptide antibodies 
and  specific  anti-β1-AR  peptide  antibodies  were 
determined by radial immunodiffusion assay, and 
their immunological reactivity against the β1-AR 
peptide was evaluated by ELISA.14
Flow cytometry procedure
Fibroblasts  were  obtained  as  described 
above.  After  washing  cells  with  PBS,  pellets 
were resuspended in PBS containing IgG  (1x10-9 
M) from patients with CP or normal subjects as 
negative controls. After a 1 hour incubation at 4ºC, 
cells were washed and incubated for 30 min with 
rabbit  anti-human  IgG  FITC-conjugated  F(ab’)2 
fragments (1:100). Cells were then fixed with 1% 
paraformaldehyide and analyzed by flow cytometry 
in a FACScan cytofluorometer (Becton Dickinson, 
Mountain View, CA, USA). An argon laser operating 
at  488  nm  exited  fluorescence  attributable  to 
FITC-conjugated  antibodies.  Emission  from 
fluorescein was measured using bandpass filters 
at  525  nm.  Appropriate  settings  of  forward  and 
side  scatter  gates  were  use  to  examine  10,000 
cells per experiment. The percentage of positive 
cells was determined by the thresholds set using 
isotopic  controls.  The  numbers  of  fluorescent 
molecules per cell were indirectly measured by 
assessing the mean intensity of arbitrary units of 
fluorescence of cells. 
Measurement of DNA synthesis  
DNA synthesis was estimated by measurement 
of [3H]-thymidine  incorporation into trichloroacetic 
acid (TCA)–precipitable material. The β adrenergic 
actions of IgG were evaluated in cells (1x106 cell/
ml) that had been serum-starved for 8 hours. Each 
concentration of IgG was in contact with the cells 
for 8 hours. When β1 adrenergic antagonistic drugs 
were used, they were added 10 min before IgG. 
The [3H]-thymidine  (0.1µCi/ml) was added during 
the  last  2  hours.  Cells  were  precipitated  twice 
with ice-cold 10% TCA and fibroblasts were then 
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removed  with  trypsin/PBS  and  radioactivity  was 
determined by liquid scintillation counting. Cells 
that had been serum-starved for 8 hours without 
drugs were used as controls (basal value). 
Membrane preparation  
Membranes  were  prepared  as  previously 
described.23 In brief, the cells (2x106 cell/ml)   were 
homogenized in an Ultraturrax at 4°C in 6 volumes 
of potassium phosphate buffer, 1 mM MgCI2, 0.25 
M sucrose  (pH 7.5) supplemented with 0.1 mM 
phenylmethyl  sulphonyl  fluoride  (PMSF),  1  mM 
EDTA, 5 µg ml-1 leupeptin, 1 µM bacitracin, and 1 
µM pepstatin A. The homogenate was centrifuged 
twice for 10 min at 3000 g, then at 10,000 g and 
40,000 g at 4°C for 15 and 90 min, respectively.   
The resulting pellets were suspended in 50 mM 
phosphate buffer fortified with the same protease 
inhibitors (pH 7.5).
ELISA assay  
Fifty  ml  of  peptide  solution  (20  µg/ml)  or 
gingival fibroblast-purified membranes (50 µg/ml) 
in 0.1 M Na2CO3 buffer (pH 9.6) was used to coat 
microtiter plates at 4°C overnight. After blocking 
the wells with 2% bovine serum albumin in PBS 
for 1 hour at 37ºC, 100 ml of a 1/30 dilution of sera 
of  different  concentrations  or  purified  IgG  from   
groups 1 and 2 were added in triplicate and allowed 
to react with the peptide for 2 hours at 37°C. After 
thoroughly washing the wells with 0.05% Tween 
20 in PBS, 100 µl of 1:6000 goat anti-human IgG 
alkaline  phosphate  conjugate  antibodies    were 
added  and  incubated  for  1  hour  at  37ºC.  After 
extensive  washing,  p-nitrophenylphosphate 
(1  mg/ml)  was  added  as  the  substrate  and  the 
reaction was stopped after 30 min. Optical density 
(OD)  were  measured  at  405  nm  with  an  ELISA 
reader. As a negative control, non-antigen paired 
wells with M1 cholinergic peptide and wells with 
no primary antiserum were also conducted. The 
results for each sample were expressed as the 
mean  ± s.e.m. of triplicate values.
Drugs
Stock  solutions  of  atenolol  and  butoxamine 
were  freshly  prepared  before  each  experiment. 
The  β1  peptide  corresponds  to  the  sequence 
of  the  second  extracellular  loop  of  the  human 
β1-AR  (HWWRA  ESDEA  RRCYN  DPKCC  DFVTN 
RC).  A  control,  unrelated  peptide  derived  from 
the  second  extracellular  loop  of  the  human  M1 
cholinoreceptor  (ERTLA  GQCYI  QFLSQ  PIITF 
GTAM) was used. Radioactive material, synthetic 
peptides,  and  β  adrenergic  antagonists  were 
from Dupont/New England Nuclear (Boston, MA, 
USA),  Sigma  Genosys  (St.  Louis,  MO,  USA)  and 
Sigma Chemical Company (St. Louis, MO, USA), 
respectively.
Statistical analysis  
Student’s t-test for unpaired values was used 
to determine the levels of significance. Analysis of 
variance (ANOVA) and a post hoc test (Dunnett´s 
method β1 and Student-Newman-Keuls test) were 
employed  when  pairwise  multiple  comparison 
procedures were necessary. Differences between 
means were considered significant at a P<.05.
RESuLtS
The  binding  capacity  of  human  normal  IgG 
(Figure  1A)  and  autoantibodies  of  patients  with 
CP (Figure 1B) incubated with fibroblast cells is 
shown.  Control  IgG  presented  low  binding  (1A: 
48±6) and IgG from patients with CP showed high 
binding in fibroblast cells (1B: 229±18). Moreover, 
when  β1  synthetic  peptide  corresponding  to  the 
second  extracellular  loop  of  human  β1-AR  were 
included in the reaction, the binding capacity of 
normal control IgG was not modified (2A: 43±6), 
while the autoantibodies of patients with CP were 
inhibited (2B: 53±5). 
Figure 2 shows the immune reactivity of sera 
from  different  groups  against  human  gingival 
fibroblast  membranes.  The  optical  density  (OD) 
values for sera from CP were significantly higher 
than that from healthy individuals (control).
To  determine  the  molecular  interaction 
between IgG and human β1-AR, OD values for each 
of  the  45  subjects  studied  against  β1  synthetic 
peptide  as  coating  antigen  are  shown  in  the 
scatterogram (Figure 3A). The immune reactivity 
of sera from CP was significantly higher than that 
from control individuals (P<.001). The OD of sera 
from   CP was always at least 3 SD from that of sera 
from  healthy  individuals  (control).  On  the  other 
hand, when unrelated peptide (M1 cholinoreceptor 
peptide) was used as a coating antigen, both the 
IgG from patients with CP and IgG from healthy 
controls gave negative results (Figure 3B).
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Figure 4 shows the concentration-dependent 
increase in OD values with affinity-purfied anti-β1 
peptide  IgG  compared  with  the  non-antipeptide 
IgG  fraction  eluted  from  the  column  from  CP 
patients  when  the  β1-AR  synthetic  peptide  was 
used as the coating antigen. The OD values of the 
anti-β1synthetic peptide IgG were always greater 
than  3  SD  of  those  of  the  non-antipeptide  IgG 
(Figure 4A). This reaction was blocked by the β1 
synthetic peptide (10-fold concentration) IgG when 
the IgG from patients with CP was incubated for 
30 min at 37ºC and then added together in the 
microtiter plates (Figure 4B). Also, atenolol (1x10-7 
M), a specific β1-AR antagonist, but not butoxamine 
(1x10-6 M),  a specific β2-AR antagonist, blocked 
the increase of OD values triggered by IgG from 
CP  (Figure  4B).  The  concentration  of  affinity-
purified  anti-β1  synthetic  peptide  IgG  (1x10-9  M) 
that maximally increased OD values corresponded 
to  a  1x10-8  M  total  IgG  concentration.  The 
non-antipeptide  IgG  fraction  eluted  from  the 
column showed OD values similar to normal IgG 
(0.122±0.02, n=20). As expected, the IgG fraction 
from normal subjects (control) purified by affinity 
chromatography with the β1 synthetic peptide gave 
negative results (data not shown).
As already shown, the serum IgG from patients 
with CP was able to react with the β1-AR human 
fibroblast  membrane;  we  studied  the  β1-AR-
mediated  effect  of  IgG  from  patients  with  CP 
patients on human gingival fibroblast proliferation 
using the incorporation of tritiated thymidine.
Figure 5A shows that the antipeptide IgG from 
patients  with  CP  decreased  DNA  synthesis  in  a 
concentration-dependent manner. Atenolol (1x10-7 
M) and β1 synthetic peptide (10-fold concentration), 
but  not  butoxamine  (1x10-6  M),  prevented  the 
inhibitory  effect  of  IgG  upon  DNA  synthesis  of 
human  gingival  fibroblasts  (Figure  5B).  Normal 
IgG was without effect on the study system.
dISCuSSIoN  
From  the  clinical  point  of  view,  the  course 
of  exacerbation  and  remissions,  genetic 
vulnerability,  and  environmental  factors17  hint 
at  parallels  between  periodontal  disease  and 
autoimmune  diseases.24  Moreover,  autoimmune 
systemic diseases, such as rheumatoid arthritis 
and adult periodontitis, share common pathogenic 
mechanisms  and  immunologic  and  pathogenic 
findings.25
The aim of our study was to examine the possible 
role of altered humoral immunity, exploring the β 
adrenergic activity of IgG from patients with CP. 
By  flow  cytometry  and  ELISA  assays,  we  have 
provided  evidence  that  certain  components  of 
Figure 1. Representative flow cytometry analysis of binding 
IgG. Culture fibroblasts were incubated with A: normal human 
IgG  (1x10-9  M)  or  B:  CP  IgG  (1x10-9  M)  alone  (1).  The  same 
concentration of normal (2 A) or CP (2 B) IgGs preincubated 
during 40 min with 1x10-5 M β1 synthetic peptide is also shown. 
Figure is representative of separated assays using antibody 
from 7 patients with CP and 6 healthy subjects with similar 
results.
Figure 2. Immunoreactivity (ELISA) of anti-membrane human 
gingival fibroblast antibodies of individual sera from groups: 
(■) 25 patients with CP and (▲) 20 healthy subjects, control. 
Sera  (1/50  dilution)  was  assayed  on  sensitized  microplates 
with 50 µg/ml of human gingival fibroblast membranes. Values 
are means±SEM. P<.001 between CP and control.
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the serum IgG fraction from patients with CP can 
recognize human gingival fibroblast membranes. 
The  titer  of  serum  antibodies  in  individuals 
with  periodontal  disease  are  often  elevated  as 
compared to healthy individuals,10 but others26,27 did 
not detect a rise in antibody levels. Furthermore, 
following disease activity episodes, the increase 
in IgG antibody often shows a shift in microbial 
specificity.28  The  level  of  antibodies  to  collagen 
type I was significantly higher in the patients with 
periodontitis than in healthy controls.12 In contrast 
to  these  observations.  Hirsch  et  al29  reported 
that  anti-collagen-producing  cells  are  rarely 
detected in peripheral blood and the levels of anti-
collagen antibodies in serum are low. Thus, serum 
antibody  detection  could  indicate  the  chronic 
exposure of antigen challenge and the presence of 
exacerbation of the disease.
The  autonomic  adrenergic  system  is  an 
important regulator of the immune response.14,30 
Therefore, in an attempt to elucidate the nature 
of  the  sympathetic  mechanism  involved,  we 
characterized the participation of the β adrenergic 
system  on  the  effect  of  serum  antibodies.  In 
this  sense,  we  demonstrated  that  patients  with 
periodontal  disease  have  functional  serum  IgG 
Figure 3. Scatterogram showing immune reactivity (ELISA) of 
sera IgG antibodies against the second extracellular loop of A: 
β1-AR and B: M1 cholinoreceptor tested by ELISA. Shown are 
the individual optical density (OD) values each sera samples 
(1/50  dilution)  from  25  patients  with  CP  (■)  and  20  healthy 
volunteers, control (▲). Datted/dashed line, cutoff value 0.242 
(mean  optical  density±SEM  for  control;  solid  lines,  median 
optical density value. P<.001 between CP and healthy subjects 
(control).
Figure 4. Recognition of synthetic β1 peptide by patients with 
CP. A: anti β1 peptide IgG (■) and non-anti β1 fraction eluted 
from the column from group 1 (●) were incubated at different 
concentrations in multiwell plates sensitized with β1 peptide 
as described in the Material and Methods section. b: Basal 
values without IgG . B: 1x10-9 M anti-β1 peptide IgG from CP 
in the absence or in the presence of 1x10-7 M atenolol or 1x10-
6 M butoxamine or 1 µg of β1 synthetic peptide. Basal values 
are also shown. Values are means±SEM of 10 patients in each 
group. ***:P<.001 between basal vs. CP IgG;  ***:P<.001 anti-β1 
peptide or atenolol+CP IgG vs. CP  IgG. 
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autoantibodies  that  interact  with  the  β1-AR  to 
human gingival fibroblasts. The high prevalence 
of these anti-β1-AR autoantibodies in periodontal 
disease  patients  provides  new  evidence  in 
interaction with other causes to be considered in 
the immunopathology of the disease. Antibodies 
against β1-AR have also been found in the sera 
of patients with other autoimmune disorders.31,32 
The  antibodies  are  able  to  interact  with  the 
second  extracellular  loop  of  the  human  β1-AR, 
which is the main immunogenic region of these 
receptors.14    The  pathogenic  properties  of  anti-
β1-AR autoantibodies have been ascribed to their 
potency to continuously stimulate the sympathetic 
system. Thus, β1-AR autoantibodies could trigger 
two  important  mechanisms.  On  the  one  hand, 
autoantibodies, by targeting cardiac β1-AR, altered 
the physiologic behavior of the myocardium,31 and 
on the other hand, it may exacerbate or maintain 
chronic inflammatory heart disease32 through the 
induction of an immune suppression response.14 In 
fact, it has been proposed that during sympathetic 
hyperactivity  there  is  a  dysregulation  of  the 
pro-  versus  anti-inflammatory  cytokines  and  T 
helper  (Th1)  versus  TH2  lymphocytes  balance. 
Thus, catecholamines and PGE2 up-regulate Th2   
lymphocytes, associated with increase in humoral 
immunity and decrease in Th1 with down-regulation 
of cell-mediate immunity (CMI).33  Then, the β1-AR 
autoantibodies  could  exacerbate  the  course  of 
the disease by altered focus of immune function 
with an up-regulation of its own production and 
suppression  of  CMI.  Although,  the  regulatory 
mechanism of autoantibodies in CP has not been 
clarified,  further  studies  are  needed  to  provide 
insight not only into the role of β1-AR autoantibodies 
in the pathogenesis of periodontitis, but also into 
the possible link between periodontitis and heart 
disease. 
The  most  important  feature  of  this  study 
relating to the autoimmune nature of CP was the 
presence of IgG in total sera, acting and fixing on 
β1-AR, resulted in a primary cell-specific growth 
inhibition. In fact, IgG from these patients were 
able to inhibit DNA synthesis of human gingival 
fibroblasts. The specificity of this interaction was 
assessed  by  inhibiting  the  IgG  effect  by  human 
β1-AR synthetic peptide and with a β1-AR specific 
antagonist  (atenolol).  Ligand  interactions  of  β1-
AR  IgG  from  CP  with  membrane  receptors  are 
the  initial  triggers  for  altering  fibroblast  cell 
function.  Deficiencies  or  modifications  in  such 
receptors  or  inappropriate  coupling  to  second 
messengers can result in dysfunctional gingival 
fibroblasts that contribute not only to connective 
tissue degradation, but also have been associated 
with progressive loss of tooth attachment.27 The 
fact that IgG from patients with CP IgG inhibited 
DNA  synthesis  indicates  the  possibility  that  IgG 
fixation to fibroblast β1-AR could cause loss of both 
connective and bone tissue, accompanied by loss of 
tooth attachment. The β1-AR are present in human 
fibroblasts where they modulate the proliferation 
with an increase in cAMP production.34
Figure 5. Inhibition of [3H]-Thymidine Incorporation of human 
gingival fibroblast by IgG from patients with CP. A: Increasing 
concentrations  of  anti-β1  peptide  IgG  (■)  and  non-anti-β1 
peptide IgG fraction (●) from CP patients were incubated with 
1x106 cells and DNA synthesis was measured as described in 
the Material and Methods section. b: basal values without IgG. 
B: 1x10-9 M anti-β1 peptide IgG from patients with CP in the 
absence or in the presence of 1x10-7 M atenolol and 1x10-6 M 
butoxamine or 1 µg of β1 synthetic peptide. Normal IgG treated 
as IgG from patients with CP was ineffective in the studied 
system. Values are means±SEM of 10 patients in each group 
performed by triplicate.  ***:P<.001   between β1 peptide or 
atenolol+CP IgG;  ***:P<.001 between CP IgG vs. normal  IgG.
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CoNCLuSIoNS
The  findings  of  this  study  support  the 
autoimmune  process  against  β1-AR  from 
fibroblasts. It can be speculated that the damage 
to periodontal tissues can expose self antigens to 
β1-AR.  Although molecular mimicry may also play 
a role in this situation but more importantly it may 
unravel  indirect  pathogenic  mechanisms  which 
interfere  with  the  effects  of  catecholamines  on 
periodontal tissues. 
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